SYNTARA LIMITED - Announcements

Market Cap $27.46M Add to my watchlist

Syntara Limited, formerly Pharmaxis Ltd, is an Australia-based clinical-stage drug... Syntara Limited, formerly Pharmaxis Ltd, is an Australia-based clinical-stage drug development company with a focus on blood-related cancers. The Company’s highly productive drug discovery engine is driven by its expertise in amine oxidase inhibitors. Its lead candidate, PXS-5505, is used for the bone marrow cancer myelofibrosis, which causes a build-up of scar tissue that leads to loss of red and white blood cells and platelets. The Company is also advancing both oral and topical pan-LOX inhibitors in scar prevention and scar modification programs. Its PXS-4728 is a SSAO/MAOB inhibitor to treat sleep disorders and slow progression of neurodegenerative diseases like Parkinson’s by reducing neuroinflammation. The Company’s other drug candidates target fibrotic and inflammatory diseases such as kidney fibrosis, NASH, pulmonary fibrosis, and cardiac fibrosis. It has developed two respiratory products: Bronchitol, for cystic fibrosis, and Aridol, a lung function test.More

Announcements

Filter Results

All Price Sensitive Only

Filters [Clear]

Price Sensitive: Yes

SNT	Quarterly Activities Report	PRICE SENSITIVE	30/04/24	201.7KB	Share
SNT	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	30/04/24	234.71KB	Share
SNT	Half Yearly Report and Accounts	PRICE SENSITIVE	29/02/24	792.29KB	Share
SNT	Quarterly Activities Report	PRICE SENSITIVE	31/01/24	343.15KB	Share
SNT	Quarterly Appendix 4C Cash Flow Report	PRICE SENSITIVE	31/01/24	223.07KB	Share
SNT	Placement	PRICE SENSITIVE	19/12/23	367.31KB	Share
SNT	Trading Halt	PRICE SENSITIVE	18/12/23	399.59KB	Share
SNT	Quarterly Activities Report	PRICE SENSITIVE	31/10/23	818.62KB	Share
SNT	Quarterly Appendix 4C Cash Flow Report	PRICE SENSITIVE	31/10/23	402.52KB	Share
SNT	PXS Company Restructure Sale of Mannitol Business	PRICE SENSITIVE	03/10/23	498.47KB	Share
SNT	Trading Halt	PRICE SENSITIVE	02/10/23	556.33KB	Share
SNT	Preliminary Final Report	PRICE SENSITIVE	28/08/23	2.05MB	Share
SNT	PXS to Receive Prepayment of 2023 Research Tax Incentive	PRICE SENSITIVE	08/08/23	188.43KB	Share
SNT	Quarterly Activities Report	PRICE SENSITIVE	31/07/23	643.63KB	Share
SNT	Quarterly Appendix 4C Cash Flow Report	PRICE SENSITIVE	31/07/23	330.79KB	Share
SNT	Final Set of Interim Data from PXS-5505 in Myelofibrosis	PRICE SENSITIVE	12/07/23	245.37KB	Share
SNT	PXS Announces Encouraging Results from Phase 1c Scar Study	PRICE SENSITIVE	23/05/23	235.37KB	Share
SNT	Trading Halt	PRICE SENSITIVE	22/05/23	369.47KB	Share
SNT	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	28/04/23	625.51KB	Share
SNT	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	28/04/23	323.77KB	Share
SNT	After FDA Review PXS Accelerates Plans for Combination Study	PRICE SENSITIVE	12/04/23	223.25KB	Share
SNT	Half Yearly Report and Accounts	PRICE SENSITIVE	10/02/23	718.73KB	Share
SNT	Quarterly Activities Report	PRICE SENSITIVE	31/01/23	529.73KB	Share
SNT	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	31/01/23	219.35KB	Share
SNT	Quarterly Activities Report	PRICE SENSITIVE	31/10/22	869.62KB	Share
SNT	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	31/10/22	219.1KB	Share
SNT	PXS announces positive interim data from myelofibrosis trial	PRICE SENSITIVE	19/10/22	257.53KB	Share
SNT	Investor Presentation	PRICE SENSITIVE	19/10/22	1.56MB	Share
SNT	Placement	PRICE SENSITIVE	19/10/22	223.88KB	Share
SNT	Trading Halt	PRICE SENSITIVE	18/10/22	372.8KB	Share
SNT	PXS Releases Promising Interim Data from Skin Scarring Study	PRICE SENSITIVE	26/09/22	182.78KB	Share
SNT	PXS to Receive Stg2.9m from Parkinsons UK for New Trial	PRICE SENSITIVE	01/09/22	208.6KB	Share
SNT	Preliminary Final Report	PRICE SENSITIVE	30/08/22	859.7KB	Share
SNT	Aptar Pharma Pays PXS Us$5m to Acquire Orbital Technology	PRICE SENSITIVE	04/08/22	167.45KB	Share
SNT	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	29/07/22	471.83KB	Share
SNT	Quarterly Appendix 4C Cash Flow Report	PRICE SENSITIVE	29/07/22	199.5KB	Share
SNT	Clarification Announcement	PRICE SENSITIVE	13/05/22	305.36KB	Share
SNT	Quarterly Activities Report	PRICE SENSITIVE	29/04/22	496.87KB	Share
SNT	Appendix 4C Quarterly Cash Flow Report	PRICE SENSITIVE	29/04/22	193.55KB	Share
SNT	Half Yearly Report and Accounts	PRICE SENSITIVE	11/02/22	402.94KB	Share
SNT	Quarterly Activities Report	PRICE SENSITIVE	31/01/22	529.16KB	Share
SNT	Quarterly Appendix 4C Cash Flow Report	PRICE SENSITIVE	31/01/22	193.78KB	Share
SNT	Response to ASX Aware Query	PRICE SENSITIVE	10/01/22	392.67KB	Share
SNT	PXS Collaborators Receive Government Grants of $1.4m	PRICE SENSITIVE	06/01/22	156.38KB	Share
SNT	Share Purchase Plan	PRICE SENSITIVE	20/12/21	145.24KB	Share
SNT	Security Purchase Plan	PRICE SENSITIVE	25/11/21	389.6KB	Share
SNT	Investor Presentation	PRICE SENSITIVE	17/11/21	2.22MB	Share
SNT	Placement	PRICE SENSITIVE	17/11/21	152.6KB	Share
SNT	Trading Halt	PRICE SENSITIVE	15/11/21	228.42KB	Share
SNT	FDA Clears PXS Cancer Drug for Phase 2 Liver Cancer Study	PRICE SENSITIVE	09/11/21	118.69KB	Share
SNT	Quarterly Activities Report	PRICE SENSITIVE	28/10/21	514.55KB	Share
SNT	Appendix 4C Cash Flow Report	PRICE SENSITIVE	28/10/21	193.16KB	Share
SNT	PXS Doses First Patient in Phase 2 Bone Marrow Cancer Trial	PRICE SENSITIVE	13/10/21	116.37KB	Share
SNT	PXS Cleared to Progress to Phase 2 Bone Marrow Cancer Trial	PRICE SENSITIVE	05/10/21	165.64KB	Share
SNT	Pharmaxis Treatment to Prevent Wound and Burns Scars Clears	PRICE SENSITIVE	31/08/21	133.42KB	Share
SNT	PXS Grants Exclusive Option to Develop High Payload Inhaler	PRICE SENSITIVE	17/08/21	169.14KB	Share
SNT	Preliminary Final Report	PRICE SENSITIVE	12/08/21	945.3KB	Share
SNT	PXS Drug Decreases Tumour Burden in Liver Cancer Model	PRICE SENSITIVE	05/08/21	132.32KB	Share
SNT	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	28/07/21	1.13MB	Share
SNT	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	28/07/21	180KB	Share
SNT	PXS Sells Australian Distribution Rights for A$2m	PRICE SENSITIVE	01/07/21	146.07KB	Share
SNT	BTC: Exclusive distribution rights for Bronchitol & Aridol	PRICE SENSITIVE	30/06/21	118.62KB	Share
SNT	PXS Announces First Results in Bone Marrow Cancer Trial	PRICE SENSITIVE	29/06/21	118.64KB	Share
SNT	Quarterly Activity Report	PRICE SENSITIVE	30/04/21	498KB	Share
SNT	Appendix 4C - quarterly	PRICE SENSITIVE	30/04/21	179.97KB	Share
SNT	Sale of Russian Distribution Rights	PRICE SENSITIVE	14/04/21	144.32KB	Share
SNT	Investor Presentation Capital Raising and Growth Outlook	PRICE SENSITIVE	14/04/21	2.45MB	Share
SNT	Placement	PRICE SENSITIVE	14/04/21	146.13KB	Share
SNT	Trading Halt	PRICE SENSITIVE	13/04/21	218.32KB	Share
SNT	First Patient Enrolled - Clinical Trial for Cancer Treatment	PRICE SENSITIVE	22/02/21	132.47KB	Share
SNT	Half Yearly Report and Accounts	PRICE SENSITIVE	10/02/21	430.36KB	Share
SNT	Pharmaxis Exports CF Drug to US - US$3 Million Milestone	PRICE SENSITIVE	09/02/21	101.56KB	Share
SNT	Appendix 4C - quarterly	PRICE SENSITIVE	29/01/21	180.59KB	Share
SNT	Quarterly Activity Report - December 2020	PRICE SENSITIVE	29/01/21	488.55KB	Share
SNT	Pharmaxis Receives US$7m milestone from Chiesi	PRICE SENSITIVE	29/12/20	96.51KB	Share
SNT	Pharmaxis Prioritises Clinical Program on Myelofibrosis	PRICE SENSITIVE	02/11/20	136.14KB	Share
SNT	FDA Approves Bronchitol for US Market	PRICE SENSITIVE	02/11/20	133.59KB	Share
SNT	Appendix 4C - quarterly	PRICE SENSITIVE	30/10/20	181.37KB	Share
SNT	September Quarter 2020 Activity Report	PRICE SENSITIVE	30/10/20	364.14KB	Share
SNT	Boehringer Ingelheim discontinues development of BI 1467335	PRICE SENSITIVE	07/09/20	684.06KB	Share
SNT	Pharmaxis Awarded $1M Australian Government Grant	PRICE SENSITIVE	03/09/20	123.9KB	Share
SNT	FDA Gives Green Light to Start Myelofibrosis Phase 2 Study	PRICE SENSITIVE	19/08/20	91.4KB	Share
SNT	Preliminary Final Report	PRICE SENSITIVE	13/08/20	934.75KB	Share
SNT	US$7 million Bronchitol Launch Milestone Brought Forward	PRICE SENSITIVE	05/08/20	101.07KB	Share
SNT	Fourth Quarter Activity Report	PRICE SENSITIVE	31/07/20	385.4KB	Share
SNT	Appendix 4C - quarterly	PRICE SENSITIVE	31/07/20	173.02KB	Share
SNT	Appendix 4C - quarterly	PRICE SENSITIVE	30/04/20	88.08KB	Share
SNT	Pharmaxis Quarterly Shareholder Update - March 2020	PRICE SENSITIVE	30/04/20	392.68KB	Share
SNT	PXS Cancer Drug Ready to Commence Phase 2 Studies Q4 2020	PRICE SENSITIVE	28/04/20	145.17KB	Share
SNT	Half Yearly Report and Accounts	PRICE SENSITIVE	13/02/20	251.24KB	Share
SNT	Appendix 4C - quarterly	PRICE SENSITIVE	31/01/20	121.39KB	Share
SNT	Quarterly Shareholder Update - December 2019	PRICE SENSITIVE	31/01/20	372.47KB	Share
SNT	Pharmaxis Business Plan Update	PRICE SENSITIVE	18/12/19	112.13KB	Share
SNT	Boehringer discontinues development of BI 1467335 for NASH	PRICE SENSITIVE	18/12/19	120.18KB	Share
SNT	Trading Halt	PRICE SENSITIVE	16/12/19	101.39KB	Share
SNT	Appendix 4C - quarterly	PRICE SENSITIVE	31/10/19	121.37KB	Share
SNT	Quarterly Shareholder Update - September 2019	PRICE SENSITIVE	31/10/19	370.87KB	Share
SNT	FDA Provides Guidance on Bronchitol Approval Steps	PRICE SENSITIVE	28/10/19	103.32KB	Share
SNT	Pharmaxis Receives $6.2m R&D Tax Incentive	PRICE SENSITIVE	17/10/19	101.81KB	Share
SNT	Preliminary Final Report	PRICE SENSITIVE	15/08/19	870.85KB	Share

SNT Quarterly Activities Report
30/04/24	PRICE SENSITIVE	201.7KB	Share
SNT Quarterly Activities/Appendix 4C Cash Flow Report
30/04/24	PRICE SENSITIVE	234.71KB	Share
SNT Half Yearly Report and Accounts
29/02/24	PRICE SENSITIVE	792.29KB	Share
SNT Quarterly Activities Report
31/01/24	PRICE SENSITIVE	343.15KB	Share
SNT Quarterly Appendix 4C Cash Flow Report
31/01/24	PRICE SENSITIVE	223.07KB	Share
SNT Placement
19/12/23	PRICE SENSITIVE	367.31KB	Share
SNT Trading Halt
18/12/23	PRICE SENSITIVE	399.59KB	Share
SNT Quarterly Activities Report
31/10/23	PRICE SENSITIVE	818.62KB	Share
SNT Quarterly Appendix 4C Cash Flow Report
31/10/23	PRICE SENSITIVE	402.52KB	Share
SNT PXS Company Restructure Sale of Mannitol Business
03/10/23	PRICE SENSITIVE	498.47KB	Share
SNT Trading Halt
02/10/23	PRICE SENSITIVE	556.33KB	Share
SNT Preliminary Final Report
28/08/23	PRICE SENSITIVE	2.05MB	Share
SNT PXS to Receive Prepayment of 2023 Research Tax Incentive
08/08/23	PRICE SENSITIVE	188.43KB	Share
SNT Quarterly Activities Report
31/07/23	PRICE SENSITIVE	643.63KB	Share
SNT Quarterly Appendix 4C Cash Flow Report
31/07/23	PRICE SENSITIVE	330.79KB	Share
SNT Final Set of Interim Data from PXS-5505 in Myelofibrosis
12/07/23	PRICE SENSITIVE	245.37KB	Share
SNT PXS Announces Encouraging Results from Phase 1c Scar Study
23/05/23	PRICE SENSITIVE	235.37KB	Share
SNT Trading Halt
22/05/23	PRICE SENSITIVE	369.47KB	Share
SNT Quarterly Activities/Appendix 4C Cash Flow Report
28/04/23	PRICE SENSITIVE	625.51KB	Share
SNT Quarterly Activities/Appendix 4C Cash Flow Report
28/04/23	PRICE SENSITIVE	323.77KB	Share
SNT After FDA Review PXS Accelerates Plans for Combination Study
12/04/23	PRICE SENSITIVE	223.25KB	Share
SNT Half Yearly Report and Accounts
10/02/23	PRICE SENSITIVE	718.73KB	Share
SNT Quarterly Activities Report
31/01/23	PRICE SENSITIVE	529.73KB	Share
SNT Quarterly Activities/Appendix 4C Cash Flow Report
31/01/23	PRICE SENSITIVE	219.35KB	Share
SNT Quarterly Activities Report
31/10/22	PRICE SENSITIVE	869.62KB	Share
SNT Quarterly Activities/Appendix 4C Cash Flow Report
31/10/22	PRICE SENSITIVE	219.1KB	Share
SNT PXS announces positive interim data from myelofibrosis trial
19/10/22	PRICE SENSITIVE	257.53KB	Share
SNT Investor Presentation
19/10/22	PRICE SENSITIVE	1.56MB	Share
SNT Placement
19/10/22	PRICE SENSITIVE	223.88KB	Share
SNT Trading Halt
18/10/22	PRICE SENSITIVE	372.8KB	Share
SNT PXS Releases Promising Interim Data from Skin Scarring Study
26/09/22	PRICE SENSITIVE	182.78KB	Share
SNT PXS to Receive Stg2.9m from Parkinsons UK for New Trial
01/09/22	PRICE SENSITIVE	208.6KB	Share
SNT Preliminary Final Report
30/08/22	PRICE SENSITIVE	859.7KB	Share
SNT Aptar Pharma Pays PXS Us$5m to Acquire Orbital Technology
04/08/22	PRICE SENSITIVE	167.45KB	Share
SNT Quarterly Activities/Appendix 4C Cash Flow Report
29/07/22	PRICE SENSITIVE	471.83KB	Share
SNT Quarterly Appendix 4C Cash Flow Report
29/07/22	PRICE SENSITIVE	199.5KB	Share
SNT Clarification Announcement
13/05/22	PRICE SENSITIVE	305.36KB	Share
SNT Quarterly Activities Report
29/04/22	PRICE SENSITIVE	496.87KB	Share
SNT Appendix 4C Quarterly Cash Flow Report
29/04/22	PRICE SENSITIVE	193.55KB	Share
SNT Half Yearly Report and Accounts
11/02/22	PRICE SENSITIVE	402.94KB	Share
SNT Quarterly Activities Report
31/01/22	PRICE SENSITIVE	529.16KB	Share
SNT Quarterly Appendix 4C Cash Flow Report
31/01/22	PRICE SENSITIVE	193.78KB	Share
SNT Response to ASX Aware Query
10/01/22	PRICE SENSITIVE	392.67KB	Share
SNT PXS Collaborators Receive Government Grants of $1.4m
06/01/22	PRICE SENSITIVE	156.38KB	Share
SNT Share Purchase Plan
20/12/21	PRICE SENSITIVE	145.24KB	Share
SNT Security Purchase Plan
25/11/21	PRICE SENSITIVE	389.6KB	Share
SNT Investor Presentation
17/11/21	PRICE SENSITIVE	2.22MB	Share
SNT Placement
17/11/21	PRICE SENSITIVE	152.6KB	Share
SNT Trading Halt
15/11/21	PRICE SENSITIVE	228.42KB	Share
SNT FDA Clears PXS Cancer Drug for Phase 2 Liver Cancer Study
09/11/21	PRICE SENSITIVE	118.69KB	Share
SNT Quarterly Activities Report
28/10/21	PRICE SENSITIVE	514.55KB	Share
SNT Appendix 4C Cash Flow Report
28/10/21	PRICE SENSITIVE	193.16KB	Share
SNT PXS Doses First Patient in Phase 2 Bone Marrow Cancer Trial
13/10/21	PRICE SENSITIVE	116.37KB	Share
SNT PXS Cleared to Progress to Phase 2 Bone Marrow Cancer Trial
05/10/21	PRICE SENSITIVE	165.64KB	Share
SNT Pharmaxis Treatment to Prevent Wound and Burns Scars Clears
31/08/21	PRICE SENSITIVE	133.42KB	Share
SNT PXS Grants Exclusive Option to Develop High Payload Inhaler
17/08/21	PRICE SENSITIVE	169.14KB	Share
SNT Preliminary Final Report
12/08/21	PRICE SENSITIVE	945.3KB	Share
SNT PXS Drug Decreases Tumour Burden in Liver Cancer Model
05/08/21	PRICE SENSITIVE	132.32KB	Share
SNT Quarterly Activities/Appendix 4C Cash Flow Report
28/07/21	PRICE SENSITIVE	1.13MB	Share
SNT Quarterly Activities/Appendix 4C Cash Flow Report
28/07/21	PRICE SENSITIVE	180KB	Share
SNT PXS Sells Australian Distribution Rights for A$2m
01/07/21	PRICE SENSITIVE	146.07KB	Share
SNT BTC: Exclusive distribution rights for Bronchitol & Aridol
30/06/21	PRICE SENSITIVE	118.62KB	Share
SNT PXS Announces First Results in Bone Marrow Cancer Trial
29/06/21	PRICE SENSITIVE	118.64KB	Share
SNT Quarterly Activity Report
30/04/21	PRICE SENSITIVE	498KB	Share
SNT Appendix 4C - quarterly
30/04/21	PRICE SENSITIVE	179.97KB	Share
SNT Sale of Russian Distribution Rights
14/04/21	PRICE SENSITIVE	144.32KB	Share
SNT Investor Presentation Capital Raising and Growth Outlook
14/04/21	PRICE SENSITIVE	2.45MB	Share
SNT Placement
14/04/21	PRICE SENSITIVE	146.13KB	Share
SNT Trading Halt
13/04/21	PRICE SENSITIVE	218.32KB	Share
SNT First Patient Enrolled - Clinical Trial for Cancer Treatment
22/02/21	PRICE SENSITIVE	132.47KB	Share
SNT Half Yearly Report and Accounts
10/02/21	PRICE SENSITIVE	430.36KB	Share
SNT Pharmaxis Exports CF Drug to US - US$3 Million Milestone
09/02/21	PRICE SENSITIVE	101.56KB	Share
SNT Appendix 4C - quarterly
29/01/21	PRICE SENSITIVE	180.59KB	Share
SNT Quarterly Activity Report - December 2020
29/01/21	PRICE SENSITIVE	488.55KB	Share
SNT Pharmaxis Receives US$7m milestone from Chiesi
29/12/20	PRICE SENSITIVE	96.51KB	Share
SNT Pharmaxis Prioritises Clinical Program on Myelofibrosis
02/11/20	PRICE SENSITIVE	136.14KB	Share
SNT FDA Approves Bronchitol for US Market
02/11/20	PRICE SENSITIVE	133.59KB	Share
SNT Appendix 4C - quarterly
30/10/20	PRICE SENSITIVE	181.37KB	Share
SNT September Quarter 2020 Activity Report
30/10/20	PRICE SENSITIVE	364.14KB	Share
SNT Boehringer Ingelheim discontinues development of BI 1467335
07/09/20	PRICE SENSITIVE	684.06KB	Share
SNT Pharmaxis Awarded $1M Australian Government Grant
03/09/20	PRICE SENSITIVE	123.9KB	Share
SNT FDA Gives Green Light to Start Myelofibrosis Phase 2 Study
19/08/20	PRICE SENSITIVE	91.4KB	Share
SNT Preliminary Final Report
13/08/20	PRICE SENSITIVE	934.75KB	Share
SNT US$7 million Bronchitol Launch Milestone Brought Forward
05/08/20	PRICE SENSITIVE	101.07KB	Share
SNT Fourth Quarter Activity Report
31/07/20	PRICE SENSITIVE	385.4KB	Share
SNT Appendix 4C - quarterly
31/07/20	PRICE SENSITIVE	173.02KB	Share
SNT Appendix 4C - quarterly
30/04/20	PRICE SENSITIVE	88.08KB	Share
SNT Pharmaxis Quarterly Shareholder Update - March 2020
30/04/20	PRICE SENSITIVE	392.68KB	Share
SNT PXS Cancer Drug Ready to Commence Phase 2 Studies Q4 2020
28/04/20	PRICE SENSITIVE	145.17KB	Share
SNT Half Yearly Report and Accounts
13/02/20	PRICE SENSITIVE	251.24KB	Share
SNT Appendix 4C - quarterly
31/01/20	PRICE SENSITIVE	121.39KB	Share
SNT Quarterly Shareholder Update - December 2019
31/01/20	PRICE SENSITIVE	372.47KB	Share
SNT Pharmaxis Business Plan Update
18/12/19	PRICE SENSITIVE	112.13KB	Share
SNT Boehringer discontinues development of BI 1467335 for NASH
18/12/19	PRICE SENSITIVE	120.18KB	Share
SNT Trading Halt
16/12/19	PRICE SENSITIVE	101.39KB	Share
SNT Appendix 4C - quarterly
31/10/19	PRICE SENSITIVE	121.37KB	Share
SNT Quarterly Shareholder Update - September 2019
31/10/19	PRICE SENSITIVE	370.87KB	Share
SNT FDA Provides Guidance on Bronchitol Approval Steps
28/10/19	PRICE SENSITIVE	103.32KB	Share
SNT Pharmaxis Receives $6.2m R&D Tax Incentive
17/10/19	PRICE SENSITIVE	101.81KB	Share
SNT Preliminary Final Report
15/08/19	PRICE SENSITIVE	870.85KB	Share

REFRESH

1 2 3

(20min delay)
Last 2.3¢		Change -0.003(11.5%)		Mkt cap ! $27.46M

Open	High	Low	Value	Volume
2.5¢	2.6¢	2.3¢	$24.39K	1.023M

Buyers (Bids)

No.	Vol.	Price($)
4	227076	2.3¢

Sellers (Offers)

Price($)	Vol.	No.
2.4¢	182499	2

View Market Depth

No.	Vol.	Price($)
4	227076	0.023
3	93000	0.022
5	793867	0.021
12	3867674	0.020
3	1026988	0.019

Price($)	Vol.	No.
0.024	182499	2
0.025	139960	2
0.027	250000	2
0.029	347870	2
0.030	358058	3

Last trade - 12.55pm 21/06/2024 (20 minute delay)


Last 2.4¢		Change -0.003 ( 7.69 %)
Open	High	Low	Volume
2.5¢	2.5¢	2.3¢	528912
Last updated 13.02pm 21/06/2024 ?

SNT (ASX) Chart

SYNTARA LIMITED - Announcements

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories